We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01333007
First Posted: April 11, 2011
Last Update Posted: November 2, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hoffmann-La Roche
April 6, 2011
April 11, 2011
November 2, 2016
July 2010
May 2013   (Final data collection date for primary outcome measure)
Progression-free survival [ Time Frame: 18 months ]
Same as current
Complete list of historical versions of study NCT01333007 on ClinicalTrials.gov Archive Site
  • Clinical (diagnosis, therapies, comorbidity) and demographic characteristics of patients initiated on Avastin treatment [ Time Frame: 18 months ]
  • Modality of treatment with Avastin (dose, duration, associated chemotherapy) [ Time Frame: 18 months ]
  • Overall survival [ Time Frame: 18 months ]
  • Safety: Incidence of adverse events [ Time Frame: 18 months ]
  • Quality of Life: Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire [ Time Frame: 18 months ]
  • Treatment of non-squamous NSCLC in clinical practice [ Time Frame: 18 months ]
Same as current
Not Provided
Not Provided
 
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
A Cohort Study of First-line Treatment of Patients With Unresectable Advanced (Stage IIIB), Metastatic (Stage IV) or Recurrent Non Squamous Non-small Cell Lung Cancer (NSCLC), Starting a Treatment With Bevacizumab (Avastin®) in Combination With Chemotherapy.
This observational study will evaluate modality, efficacy and safety of Avastin (bevacizumab) as first-line treatment in combination with chemotherapy in patients with inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer in clinical practice. Data will be collected for each patient for 18 months from initiation of Avastin therapy.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
Non-Squamous Non-Small Cell Lung Cancer
Not Provided
Cohort
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
423
May 2013
May 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Inoperable advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)
  • Treating physician's decision to initiate first-line Avastin treatment

Exclusion Criteria:

  • Participation in a clinical trial evaluating anti-cancer therapies
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT01333007
ML22991
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
November 2016